Ignet

Gene Information

Gene symbol: TFAP2B

Gene name: transcription factor AP-2 beta (activating enhancer binding protein 2 beta)

HGNC ID: 11743

Synonyms: AP2-B

Related Genes

#	Gene Symbol	Number of hits
1	ADIPOQ	1 hits
2	BDNF	1 hits
3	ETV5	1 hits
4	FADS1	1 hits
5	FTO	1 hits
6	GCKR	1 hits
7	GNPDA2	1 hits
8	IL6	1 hits
9	INS	1 hits
10	KCTD15	1 hits
11	LEP	1 hits
12	LYPLAL1	1 hits
13	MAF	1 hits
14	MAP2K5	1 hits
15	MC4R	1 hits
16	MSRA	1 hits
17	MTCH2	1 hits
18	MTMR9	1 hits
19	NEGR1	1 hits
20	NRXN3	1 hits
21	SCG3	1 hits
22	SEC16B	1 hits
23	SH2B1	1 hits
24	TMEM18	1 hits
25	TNF	1 hits
26	TNNI3K	1 hits
27	WNT5B	1 hits

Related Sentences

#	PMID	Sentence
1	16373396	In an experiment using adenovirus vectors encoding TFAP2B, the expression of TNF-alpha gene was shown to be elevated in the TFAP2B overexpressing cells compared with those in control cells.
2	16373396	Furthermore, we demonstrated that the expression of TFAP2B was increased in the adipose tissues of subjects with the disease-susceptibility allele, and the plasma levels of TNF-alpha and high sensitivity C-reactive peptide were significantly elevated in the patients with the disease-susceptibility allele.
3	16373396	In an experiment using adenovirus vectors encoding TFAP2B, the expression of TNF-alpha gene was shown to be elevated in the TFAP2B overexpressing cells compared with those in control cells.
4	16373396	Furthermore, we demonstrated that the expression of TFAP2B was increased in the adipose tissues of subjects with the disease-susceptibility allele, and the plasma levels of TNF-alpha and high sensitivity C-reactive peptide were significantly elevated in the patients with the disease-susceptibility allele.
5	17458225	[Role of TFAP2B and Wnt5B in adipose tissue].
6	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
7	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
8	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
9	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
10	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
11	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
12	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
13	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
14	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
15	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
16	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
17	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
18	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
19	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
20	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
21	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
22	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
23	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
24	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
25	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
26	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
27	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
28	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
29	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
30	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
31	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
32	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
33	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
34	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
35	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
36	19325541	The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.
37	19325541	A transcription factor, TFAP2B, has been shown to participate in the regulation of adipocyte metabolism, by facilitating glucose uptake and lipid accumulation, while simultaneously reducing insulin sensitivity, and recently a direct function for TFAP2B as an inhibitor of adiponectin expression was observed.
38	19325541	In this study, we have investigated how insulin resistance, plasma adiponectin, and central adiposity, in a normal population of adolescents, are affected by genetic variability in TFAP2B.
39	19325541	Our results show that both insulin sensitivity, as measured from levels of fasting glucose and insulin, and central adiposity, estimated by subscapular skinfold thickness, were significantly associated to genetic variability in TFAP2B.
40	19325541	Levels of adiponectin did not show any association to the TFAP2B polymorphism, but was negatively correlated to central adiposity in females.
41	19325541	These results suggest that reduction of TFAP2B expression could have a protective effect against future risk of complications associated with decreased insulin sensitivity and central adiposity, such as type 2 diabetes and coronary heart disease.
42	20019683	To determine the potential role of the transcriptional factor-activating enhancer-binding protein-2beta (TFAP2B) in the regulation of expression of adipokines, adiponectin, leptin, and interleukin-6 (IL-6) in vivo, we quantified the mRNA expression levels of these adipokines and TFAP2B in visceral (omental) and abdominal subcutaneous adipose tissues of 66 individuals with variable degree of adiposity and studied their correlations with BMI and their plasma concentrations.
43	20019683	Whereas TFAP2B mRNA expression did not correlate with BMI, it correlated negatively with adiponectin expression in the subcutaneous adipose tissue.
44	20019683	Furthermore, TFAP2B mRNA expression correlated negatively with leptin and positively with IL-6 expression in both subcutaneous and omental adipose tissues.
45	20019683	To determine the potential role of the transcriptional factor-activating enhancer-binding protein-2beta (TFAP2B) in the regulation of expression of adipokines, adiponectin, leptin, and interleukin-6 (IL-6) in vivo, we quantified the mRNA expression levels of these adipokines and TFAP2B in visceral (omental) and abdominal subcutaneous adipose tissues of 66 individuals with variable degree of adiposity and studied their correlations with BMI and their plasma concentrations.
46	20019683	Whereas TFAP2B mRNA expression did not correlate with BMI, it correlated negatively with adiponectin expression in the subcutaneous adipose tissue.
47	20019683	Furthermore, TFAP2B mRNA expression correlated negatively with leptin and positively with IL-6 expression in both subcutaneous and omental adipose tissues.
48	20019683	To determine the potential role of the transcriptional factor-activating enhancer-binding protein-2beta (TFAP2B) in the regulation of expression of adipokines, adiponectin, leptin, and interleukin-6 (IL-6) in vivo, we quantified the mRNA expression levels of these adipokines and TFAP2B in visceral (omental) and abdominal subcutaneous adipose tissues of 66 individuals with variable degree of adiposity and studied their correlations with BMI and their plasma concentrations.
49	20019683	Whereas TFAP2B mRNA expression did not correlate with BMI, it correlated negatively with adiponectin expression in the subcutaneous adipose tissue.
50	20019683	Furthermore, TFAP2B mRNA expression correlated negatively with leptin and positively with IL-6 expression in both subcutaneous and omental adipose tissues.
51	21674055	Implications of central obesity-related variants in LYPLAL1, NRXN3, MSRA, and TFAP2B on quantitative metabolic traits in adult Danes.
52	21686128	Three loci were recently identified for central adiposity from a genome wide association study (MSRA [rs545854; G/C], LYPLAL1 [rs2605100; G/A], TFAP2B [rs987237; A/G]).
53	21686128	Carriers of the TFAP2B risk variant, however, had lower leptin levels (-2.7 ng/ml, p=0.005).
54	21686128	Three loci were recently identified for central adiposity from a genome wide association study (MSRA [rs545854; G/C], LYPLAL1 [rs2605100; G/A], TFAP2B [rs987237; A/G]).
55	21686128	Carriers of the TFAP2B risk variant, however, had lower leptin levels (-2.7 ng/ml, p=0.005).
56	21796137	Association of variations in the FTO, SCG3 and MTMR9 genes with metabolic syndrome in a Japanese population.
57	21796137	There is evidence that obesity and obesity-related phenotypes are associated with variations in several genes, including NEGR1, SEC16B, TMEM18, ETV5, GNPDA2, BDNF, MTCH2, SH2B1, FTO, MAF, MC4R, KCTD15, SCG3, MTMR9, TFAP2B, MSRA, LYPLAL1, GCKR and FADS1.
58	21796137	Four SNPs in the FTO gene were significantly related to metabolic syndrome: rs9939609 (P=0.00013), rs8050136 (P=0.00011), rs1558902 (P=6.6 × 10(-5)) and rs1421085 (P=7.4 × 10(-5)). rs3764220 in the SCG3 gene (P=0.0010) and rs2293855 in the MTMR9 gene (P=0.0015) were also significantly associated with metabolic syndrome.
59	21796137	SNPs in the FTO, SCG3 and MTMR9 genes had no SNP × SNP epistatic effects on metabolic syndrome.
60	21796137	Our data suggest that genetic variations in the FTO, SCG3 and MTMR9 genes independently influence the risk of metabolic syndrome.
61	22041983	Eight loci, rs10968576 (BDNF), rs3817334 (MTCH2), rs1558902 (FTO), rs571312 (MC4R), rs543874 (SEC16B), rs987237 (TFAP2B), rs2867125 (TMEM18) and rs7138803 (FAIM2), were previously known obesity susceptibility loci, and the remaining four loci, rs1514175 (TNNI3K), rs206936 (NUDT3), rs4771122 (MTIF3) and rs2241423 (MAP2K5), were newly identified as BMI loci by the GIANT study.